Gilde Healthcare

What Gilde Healthcare does

Gilde Healthcare is a specialist private investment firm founded in 1985 and headquartered in Utrecht, the Netherlands, with additional offices in Frankfurt am Main, Germany and Boston, Massachusetts. The firm manages approximately €3 billion in assets across three dedicated fund strategies: Venture&Growth (equity investments of up to €50 million in healthtech and therapeutics companies in Europe and North America, typically as significant minority positions); Private Equity (majority ownership in profitable lower mid-market healthcare companies in Northwestern Europe with EBITDA between €2–15 million, spanning pharma & life sciences, medtech & diagnostics, healthcare providers, and healthcare IT & outsourced services); and Climate Solutions (launched in February 2026 with an initial close of €250 million targeting €325 million, focused on profitable lower mid-market companies in energy transition, biodiversity, and waste/pollution in Benelux and DACH under SFDR Article 9). The firm employs roughly 60 sector specialists with transatlantic operating, scientific, and financial backgrounds, sourced from prior roles at McKinsey, Bain, PwC, Philips, EQT, 3i, PureTech Health, and other leading institutions.

The firm generates revenue through fund management fees on committed and invested capital, supplemented by carried interest from exits of portfolio companies across all three strategies. Notable realized exits include Inari Medical (NASDAQ IPO at $5B+ valuation in 2020), Symeres (sold to Keensight Capital), RAD-x (sold to a Swiss Life Asset Managers and Vesper Infrastructure Fund I consortium), and Performation (sold to Enovation/Legrand in 2025). The Venture&Growth portfolio of 69 active companies includes Inari Medical, Withings, Big Health, Amphista Therapeutics (with major collaborations with Bristol Myers Squibb and Merck), SpyGlass Pharma (NASDAQ IPO February 2026), and Endovascular Engineering. The Private Equity portfolio of 24 companies includes a Surgical Instrument Contract Manufacturing Group (Chr. Diener, Koscher & Würtz, Rudischhauser), EUROPIN/Acti-Med needle platform, KLIFO pharma consultancy, Physio CKI physiotherapy group, and a recently merged global fNIRS neuroimaging platform (Artinis/NIRx). The firm is regulated by the Dutch Authority for the Financial Markets (AFM) under AIFMD license, is a UN PRI signatory since 2019, and operates with no external parent or public ownership.

Name

Gilde Healthcare

Legal name

Gilde Healthcare Partners BV

Website

https://gildehealthcare.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

Gilde Healthcare is a specialist private investment firm managing €3 billion across three strategies — Venture&Growth in healthcare, Private Equity in healthcare, and Climate Solutions — serving portfolio companies in Europe and North America from offices in Utrecht, Frankfurt, and Boston.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity and Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Healthcare private equity
• Healthtech venture capital
• Medical device investment
• Climate solutions investing
• Biopharmaceutical venture growth

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management: Gilde Healthcare generates revenue through management fees and carried interest from its three fund strategies: Venture&Growth, Private Equity, and Climate Solutions. The firm manages €3 billion in assets under management across these strategies.
2. Investment Returns: Returns generated through capital appreciation and exits of portfolio companies, including IPOs, acquisitions, and trade sales. Examples include successful exits such as Inari Medical (NASDAQ listing, $5B+ valuation), Symeres (sold to Keensight Capital), Performation (sold to Enovation/Legrand), and RAD-x (sold to Swiss Life Asset Managers).

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Gilde Healthcare is a specialist private investment firm managing €3 billion across three fund strategies: Venture&Growth (healthtech and therapeutics equity investments up to €50 million in Europe and North America), Private Equity (majority buyouts of profitable lower mid-market healthcare companies in Northwestern Europe with €2-15 million EBITDA), and Climate Solutions (lower mid-market investments in energy transition, biodiversity, and waste/pollution in Benelux and DACH region). The firm provides capital, sector expertise, hands-on operating support, buy-and-build execution, and international expansion guidance to portfolio companies.

Product overview

Gilde Healthcare is a specialized private investment firm with €3 billion under management across three fund strategies: Venture&Growth in Healthcare (investing in healthtech and therapeutics), Private Equity in Healthcare (investing in lower mid-market healthcare providers and medical product suppliers), and Climate Solutions (investing in energy transition, biodiversity, and waste/pollution companies). The firm's portfolio includes various healthcare companies such as Performation (healthcare business intelligence), Inari Medical (medical devices for venous conditions), Withings (connected health devices), and Amphista Therapeutics (targeted protein degradation therapeutics).

Differentiator

Problem solved

Functional benefit

Products and services

• Venture&Growth Fund
• Private Equity Fund (Healthcare)
• Climate Solutions Fund

Quantifiable outcome

• Inari Medical grew from $250,000 Q1 2018 to projected $600 million in 2024, achieving $5B+ valuation on NASDAQ
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Artinis Medical Systems and NIRx Medical TechnologiescoreStrategic or Co-development Partner · 8 July 2025Gilde Healthcare merged Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States) into a global leader in functional Near-Infrared Spectroscopy (fNIRS) solutions. Combined entity aims to accelerate innovation and develop into leading platform for neuroimaging research tools.
• Amphista Therapeutics - Merck CollaborationcoreStrategic or Co-development Partner · 4 May 2022Amphista Therapeutics, a Gilde Healthcare portfolio company, entered a strategic collaboration with Merck with potential value up to $1.0 billion for targeted protein degradation therapeutics using Amphista's Eclipsys platform.
• Amphista Therapeutics - Bristol Myers Squibb CollaborationcoreStrategic or Co-development Partner · 1 January 2021Amphista Therapeutics entered a strategic collaboration with Bristol Myers Squibb with potential value up to $1.25 billion for next-generation targeted protein degradation medicines.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• EQT Life Sciences: EQT's healthcare-focused venture/growth arm (formerly LSP) invests across Europe and North America in therapeutics and medtech with similar check sizes; directly competes with Gilde's Venture&Growth strategy for healthcare innovation deals.
• Gimv: Belgian-listed European PE/VC firm with a dedicated Health & Care platform investing in lower mid-market healthcare companies across Benelux and DACH—the same geographic and segment focus as Gilde Healthcare Private Equity.
• Ampersand Capital Partners: US-based specialist healthcare and life sciences PE firm investing in profitable lower mid-market companies in pharma services, diagnostics, and medical devices—directly comparable to Gilde's healthcare buyout strategy.
• Linden Capital Partners: US healthcare-dedicated PE firm focused on profitable lower mid-market businesses across healthcare services, products, and distribution; closely mirrors Gilde's profitable lower mid-market healthcare PE mandate.
• Kurma Partners: Paris-based European healthcare VC firm with BioFund III investing in therapeutics and healthtech—directly comparable to Gilde's European therapeutics venture/growth strategy.
• Avista Capital Partners: US healthcare-focused PE firm investing across pharma, medtech, and healthcare services in lower mid-market and growth segments—similar sector breadth and stage focus as Gilde.
• Frazier Healthcare Partners: US healthcare-dedicated PE/VC firm with growth and buyout strategies across pharma, medtech, and healthcare services—directly comparable in approach to Gilde's combined Venture&Growth and Private Equity funds.
• Forbion: Dutch-headquartered European life sciences VC firm investing in therapeutics and medtech companies; comparable to Gilde's therapeutics venture strategy with overlapping European biotech deal flow.
• Apposite Capital: London-based specialist healthcare PE firm focused exclusively on profitable lower mid-market healthcare businesses in Europe—directly comparable to Gilde Healthcare's PE fund in mandate, geography, and target size.

Broad incumbents

• Novo Holdings: Danish holding company of the Novo Nordisk Foundation with substantial healthcare venture/PE operations across multiple stages and geographies—a much larger incumbent in healthcare investing with overlapping therapeutic and medtech exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gilde-healthcare-partners
• Xx.com/gildehealthcare

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Investments136 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilde Healthcare